La cadena de opciones muestra datos clave de las opciones de acciones de Hepion Pharmaceuticals a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Hepion Pharmaceuticals..

Hepion Pharmaceuticals (NASDAQ:HEPA) Bolsa, Cadena de Opciones

Hepion Pharmaceuticals

Hepion Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on the development of drug therapy for the treatment of chronic liver diseases. This therapeutic approach targets fibrosis and hepatocellular carcinoma associated with non-alcoholic steatohepatitis, viral hepatitis, and other liver diseases. Its cyclophilin inhibitor, Rencofilstat, is being developed to offer benefits to address these multiple complex pathologies. Rencofilstat is a pan-cyclophilin inhibitor that targets multiple pathologic pathways involved in the progression of liver disease.

Hepion Pharmaceuticals, Inc. - Common Stock

Hepion Pharmaceuticals Inc

Macquarie analyst Tim Nollen maintains Comcast (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCSA#NASDAQ">CMCSA</a>) with a Neutral and raises the price target from $40 to $42.

News

Price Target

Analyst Ratings

CMCSA

Macquarie Maintains Neutral on Comcast, Raises Price Target to $42

Tharimmune, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THAR#NASDAQ">THAR</a>) shares initially traded higher on Monday, but have since reversed after the company presented clinical data at the 75th American Association for the Study of Liver Disease (AASLD) meeting. Here&#8217;s what you <a href="https://www.benzinga.com/general/biotech/24/11/42034740/tharimmune-announces-presentation-at-aasld-the-liver-meeting">need to know.</a>
What To Know: Tharimmune, a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, presented positive clinical data from a Phase I trial of TH104, a potential treatment for chronic pruritus in chronic liver disease.
The clinical data showed that higher levels of TH104 in the blood were associated with a reduction in itching, a common symptom of chronic pruritus. The treatment also appeared safe, with no serious side effects reported.
&#8220;We look forward to initiating a Phase 2 multiple-ascending dose trial in the coming months to evaluate TH104 in chronic pruritus in primary biliary cholangitis (PBC) patients, with topline data expected in 2025. In the meantime, we continue to engage with both U.S. and EU regulatory authorities,&#8221; said Randy Milby, CEO of Tharimmune.
How To Buy THAR Shares
By now you're likely curious about how to participate in the market for Tharimmune &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy ‘fractional shares,' which allows you to own portions of stock without buying an entire share.
In the case of Tharimmune, which is trading at $1.93 as of publishing time, $100 would buy you 51.81 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to ‘go short' a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
See Also: <a href="https://www.benzinga.com/general/education/24/11/42017619/heres-how-much-100-in-bitcoin-could-be-worth-in-2030-if-cathie-woods-price-target-is-reached">Here&#8217;s How Much $100 In Bitcoin Could Be Worth In 2030 If Cathie Wood&#8217;s Price Target Is Reached</a>
THAR Price Action: At the time of publication, Tharimmune shares were down 8.29% at $1.99, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Image: Photo by roberto-sorin for Unsplash

Movers

THAR

What's Going On With Tharimmune Shares Monday?

Inflation is expected to surge back to 3% should the incoming Republican administration proceed with a potential universal tariff on imports, Goldman Sachs economist David Mericle said in a <a href="https://www.benzinga.com/news/econ-s">Sunday note.</a>
The sweeping trade measure, floated by President-elect Donald Trump, could complicate the Federal Reserve's efforts to keep inflation anchored at 2% and potentially slow the pace of rate cuts in 2025.
<h3 class="wp-block-heading">Could Tariffs Push Inflation Back To 3%?</h3>
Goldman Sachs estimates that a potential universal tariff would raise core personal consumption expenditures (PCE) inflation — the Fed&#8217;s favorite inflation gauge — by 0.9-1.2 percentage points (pp) at its peak, pushing inflation back to 3%.
"Our analysis of past tariffs suggests that every 1pp increase in the effective tariff rate raises core PCE prices by 0.1pp," Mericle said.
Under the Republican baseline scenario, more targeted tariffs on imports from China and autos are likely to increase the effective tariff rate by 3-4pp, adding 0.3-0.4pp to core PCE inflation. 
This would nudge inflation to 2.4% by December 2025. However, the implementation of a 10% universal tariff would triple this impact, causing a much sharper price surge.
While the inflationary bump is expected to be a one-time effect, such a move would force Fed policymakers to rethink the roadmap for rate cuts. 
<h3 class="wp-block-heading">Tariff Risks: China, Autos, and Beyond</h3>
The baseline scenario includes a 20 percentage point (pp) increase in tariffs on Chinese imports—less for consumer goods and as much as 60pp for non-consumer items. Tariffs on auto imports, which were hotly debated during Trump's first term, are also expected to return.
Goldman Sachs views these measures as disruptive but manageable, given their moderate inflationary impact. However, the specter of a 10%-20% universal tariff on all imports raises the stakes. 
If enacted, such a policy could shave 0.75-1.25pp off GDP growth, depending on whether it is offset by additional fiscal stimulus, such as tax cuts.
<h3 class="wp-block-heading">Tax Cuts And Spending: Fiscal Stimulus Expected To Rise</h3>
On the fiscal front, Republicans are likely to extend the 2017 tax cuts, which are set to expire in 2025, according to Goldman Sachs. 
The extension includes reinstating certain expired business investment incentives and adding modest personal tax cuts worth 0.2% of GDP.
Currently, the deficit sits at about 5% of GDP higher than historical norms for an economy operating at full employment. Meanwhile, the U.S. debt-to-GDP ratio is approaching record highs at 120%, raising concerns about fiscal sustainability.
Goldman Sachs warns that these imbalances could push bond yields higher, tightening financial conditions and creating additional headwinds for economic growth.
<h3 class="wp-block-heading">The Fed's Balancing Act: What's Next For Interest Rates?</h3>
Despite fiscal and tariff uncertainties, the Federal Reserve remains on track to cut interest rates in 2024 and 2025. Goldman expects the terminal rate to settle between 3.25% and 3.5%, higher than last cycle's 2.25%-2.5%.
"Non-monetary tailwinds, like fiscal deficits and resilient risk sentiment, are offsetting the drag from higher rates," said Mericle. 
Yet, the expert warns that fiscal imbalances and potential tariff shocks could complicate the Fed's strategy, especially if inflationary pressures or market volatility resurface.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/24/11/42013424/trumps-musk-ramaswamy-doge-plan-what-it-means-for-defense-and-it-stocks">Trump&#8217;s DOGE Plan: Goldman Sachs Says Defense Stocks Face Risks, IT Firms Could Win</a></li>
</ul>

Government

Macro Economic Events

Politics

Econ #s

Economics

Federal Reserve

Inflation Could Surge To 3% If Trump Applies Universal Tariffs: Goldman Sachs

Piper Sandler analyst Mark Lear downgrades EOG Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EOG#NYSE">EOG</a>) from Overweight to Neutral and raises the price target from $147 to $149.

Downgrades

Piper Sandler Downgrades EOG Resources to Neutral, Raises Price Target to $149

Dell Technologies Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>) shares are trading higher Monday after the company announced boosts in its AI enterprises with Dell AI factory advancements and <a href="https://www.benzinga.com/pressreleases/24/11/n42036410/dell-technologies-boosts-ai-for-enterprises-with-dell-ai-factory-advancements">new AI infrastructure</a>.
What Happened: Dell announced an expansion of its&nbsp;Dell Integrated Rack Scalable Systems (IRSS)&nbsp;program&nbsp;to include the&nbsp;Dell PowerEdge XE9685L&nbsp;and&nbsp;Dell PowerEdge XE7740&nbsp;servers in the standard 19-inch Dell Integrated Rack 5000. The new liquid and air-cooled Dell PowerEdge XE servers&nbsp;deliver advanced compute at scale and simplify data access for AI.
Dell plans to support the upcoming&nbsp;Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) GB200&nbsp;Grace Blackwell&nbsp;NVL4 Superchip with a new Dell PowerEdge XE server designed for the&nbsp;Dell IR7000. CEO Michael Dell announced Sunday that the Nvidia GB200 NVL72 server racks are now shipping.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">The 1st in the world <a href="https://twitter.com/nvidia?ref_src=twsrc%5Etfw">@nvidia</a> GB200 NVL72 server racks are now shipping. We are thrilled to deliver our liquid-cooled PowerEdge XE9712 to <a href="https://twitter.com/CoreWeave?ref_src=twsrc%5Etfw">@CoreWeave</a>. The AI rocket just got a massive boost! &#x1f916;&#x1f680;&#x1f91d; <a href="https://t.co/2QzlxbQE5f">pic.twitter.com/2QzlxbQE5f</a>
&mdash; Michael Dell (@MichaelDell) <a href="https://twitter.com/MichaelDell/status/1858306164775379268?ref_src=twsrc%5Etfw">November 18, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/42036010/alphabet-on-trial-doj-remedies-loom-but-analyst-sees-20-upside-as-discount-to-meta-narrows#google_vignette">Alphabet Braces For DOJ Remedies: Analyst Sees 20% Upside Despite &#8216;Worst Possible&#8217; Risks</a>
Dell also announced updates to the Dell Data Lakehouse to provide enterprises with modern architectures for managing and analyzing data for AI tasks.&nbsp;The Data Lakehouse updates are currently available.
Dell Validated Designs for AI PCs, services for data centers, design services for networking and implementation services for AI are also available now. The Dell PowerEdge XE9685L&nbsp;will be available in the first quarter, with the Dell PowerEdge XE7740&nbsp;expected to follow in the second quarter. 
&#8220;Getting AI up and running across a company can be a real challenge. We&#8217;re making it easier for our customers with new AI infrastructure, solutions and services that simplify AI deployments, paving the way for smarter, faster ways to work and a more adaptable future,&#8221; said&nbsp;Arthur Lewis, president, Infrastructure Solutions Group, Dell Technologies.
Dell is due to report <a href="https://www.benzinga.com/calendars/earnings">third-quarter financial results</a> after the market close on Nov. 26. Analysts expect the company to report earnings of $2.04 per share and revenue of $24.65 billion, according to estimates from <a href="http://pro.benzinga.com">Benzinga Pro</a>.
DELL Price Action: <a href="http://benzinga.com/quote/dell">Dell shares</a> were up 4.52% at $137.59 at the time of publication, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Shutterstock.

DELL

NVDA

What's Going On With Dell Technologies Stock Monday?

ZETA

Zeta Global Form4 Filing Shows ACI Investment Partners Bought 53,676 Shares At An Average Price Of $19.24/Share

What do Jeff Bezos,<a href="https://www.benzinga.com/personal-finance/24/10/41145078/billionaire-bill-gates-has-a-bold-plan-to-shrink-the-wealth-of-the-rich-heres-how-he-intends-to-"> Bill Gates</a> and Sam Altman share? Besides their fame as tech innovators – Bezos with Amazon, Gates with Microsoft and Altman with OpenAI – they&#8217;re united in betting on nuclear energy. And they're not alone.&nbsp;
The nuclear sector is experiencing a renaissance, bolstered by climate goals and energy demands, with these billionaires leading the charge.
Don't Miss:
<ul>
<li>‘Scrolling to UBI': Deloitte's #1 fastest-growing software company allows users to earn money on their phones –<a href="https://www.benzinga.com/money/mode-mobile-2"> invest today with $1,000 for just $0.25/share</a></li>
<li>This Adobe-backed AI marketing startup went from a $5 to $85 million valuation working with brands like L'Oréal, Hasbro, and Sweetgreen in just three years –<a href="https://www.benzinga.com/money/rad-ai"> here's how there's a limited time opportunity to invest at $1,000 for only $0.50/share before it closes in a few days.</a></li>
</ul>
With over $100 billion net worth, Gates founded TerraPower, a company developing next-gen nuclear reactors. TerraPower's advanced reactor, Natrium, received a $2 billion boost from the U.S. Department of Energy, along with $1 billion in private funding.&nbsp;
Gates' investment is revolutionary. It uses molten salt for energy storage, which could help integrate renewable sources into the grid more effectively.
Bezos, worth an estimated $228 billion, has invested in General Fusion, a Canadian company focused on commercializing fusion energy. Fusion, often called the &#8220;holy grail&#8221; of clean energy, replicates the sun&#8217;s energy processes. While viable fusion power remains decades away, General Fusion's progress has attracted major backers, including Bezos.
<a href="https://www.benzinga.com/topic/sam-altman">Sam Altman,</a> worth around $1 billion, focuses on advanced fission through Oklo, a startup that aims to commercialize micro-reactors that can run on nuclear waste.
Trending: This rooftop wind turbine is taking on a market projected to reach over $900 billion by 2032 –<a href="https://www.benzinga.com/money/halcium"> With already over 40,000 users signing up to purchase, here's a chance to be an early investor today!</a>
At a Bloomberg event during the World Economic Forum's annual meeting in Davos, Altman said, "There's no way to get there without a breakthrough. We need [nuclear] fusion or we need like radically cheaper solar plus storage or something at massive scale."&nbsp;
These billionaires echo that the world needs more power – fast. According to the International Energy Agency (IEA), global electricity demand is projected to increase by more than 50% by 2050. Data centers, AI applications and electric vehicles are major drivers of this surge. Goldman Sachs Research predicts data center power demand will increase by 160% by 2030. Data centers account for 1-2% of global power consumption.
Nuclear power is uniquely positioned to meet this. According to the Department of Energy, nuclear plants provide a steady and reliable energy supply. This is unlike wind and solar power, which are intermittent and dependent on weather.&nbsp;
See Also: The global games market is projected to generate $272B by the end of the year –<a href="https://www.benzinga.com/money/gameflip"> for $0.55/share, this VC-backed startup with a 7M+ userbase gives investors easy access to this asset market.</a>
The capacity factor of nuclear power – the percentage of time it operates at maximum capacity – exceeds 90%, far outpacing wind (35%) and solar (25%).
Critics argue about costs and waste, but nuclear's footprint is minuscule compared to fossil fuels. The Nuclear Energy Institute (NEI) reports nuclear energy helps avoid over 400 million metric tons of CO2 emissions yearly in the U.S., equivalent to taking 100 million cars off the road.
Nuclear energy isn't just for billionaires; governments are stepping up too. The Inflation Reduction Act in the U.S. provides $6 billion toward nuclear energy, ensuring the industry&#8217;s growth aligns with climate goals.
Read Next:
<ul>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">You can still get 4,000 of its pre-IPO shares for with $1,000 for just $0.25/share</a></li>
<li>With over 7.8K investors including Meta, Google, And Amazon Execs — this AI Startup's valuation has skyrocketed from $5 million to $85 million in just three years. <a href="https://www.benzinga.com/money/rad-ai-2">Be an early investor with just $1,000 for only $0.50/share today before the offer closes in the next few days</a>!</li>
</ul>

Startups

Billionaires Like Gates, Bezos And Altman Are Backing Nuclear Energy. Here's Why They're All In – And If You Should Be Too

Simon Property Group's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPG#NYSE">SPG</a>) short percent of float has fallen 9.06% since its last report. The company recently reported that it has 5.19 million shares sold short, which is 2.41% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.81 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Simon Property Group Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731948322_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Simon Property Group has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Simon Property Group's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Simon Property Group's peer group average for short interest as a percentage of float is 4.78%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

Peering Into Simon Property Group's Recent Short Interest

Paylocity Holding's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PCTY#NYSE">PCTY</a>) short percent of float has fallen 33.16% since its last report. The company recently reported that it has 1.12 million shares sold short, which is 2.58% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.9 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Paylocity Holding Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731948317_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Paylocity Holding has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Paylocity Holding's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Paylocity Holding's peer group average for short interest as a percentage of float is 5.86%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

PCTY

(PCTY) - Analyzing Paylocity Holding's Short Interest

UBS Gr's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBS#NYSE">UBS</a>) short percent of float has fallen 26.67% since its last report. The company recently reported that it has 6.85 million shares sold short, which is 0.22% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.11 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>UBS Gr Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731948312_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for UBS Gr has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing UBS Gr's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, UBS Gr's peer group average for short interest as a percentage of float is 1.83%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Peering Into UBS Gr's Recent Short Interest

<a href="https://www.bnnbloomberg.ca/business/company-news/2024/11/18/prominent-wall-street-bear-wilson-sets-bullish-us-stocks-target/" title="https://www.bnnbloomberg.ca/business/company-news/2024/11/18/prominent-wall-street-bear-wilson-sets-bullish-us-stocks-target/">https://www.bnnbloomberg.ca/business/company-news/2024/11/18/prominent-wall-street-bear-wilson-sets-bullish-us-stocks-target/</a>

Guidance

Morgan Stanley Is Moving Its Rating On U.S. Stocks To Overweight, And Targeting 6,500 At The End Of 2025, Compared To A June 2025 Target Of 5,400; Its New Base Target Is Above Its Previous "Bull" Scenario, Which Was 6,350. Now It Says The S&P Could Jump As High As 7,400 Next Year

WIIM

Safe and Green Development shares are trading lower after the company announced a prospectus for resale of 1.29 million shares by selling stockholders. Also, the company announced an amended ELOC purchase agreement.

HC Wainwright &amp; Co. analyst Scott Buck reiterates Enthusiast Gaming Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EGLX#NASDAQ">EGLX</a>) with a Buy and maintains $0.5 price target.

Reiteration

EGLX

HC Wainwright & Co. Reiterates Buy on Enthusiast Gaming Hldgs, Maintains $0.5 Price Target

Marked and rapid reductions in both pericarditis pain and inflammation &nbsp;maintained throughout the 26-week study
Episodes of pericarditis per year substantially reduced
MAvERIC-Pilot results support advancing CardiolRx&#x2122; into the Phase II/III MAVERIC-2 and the Phase III MAVERIC-3 clinical trials
Toronto, Ontario--(Newsfile Corp. - November 18, 2024) - Cardiol Therapeutics Inc. (NASDAQ:<a href="https://www.benzinga.com/stock/CRDL#NASDAQ">CRDL</a>) (TSX:<a href="https://www.benzinga.com/stock/CRDL#TSX">CRDL</a>) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, today reported clinical results from its Phase II open-label MAvERIC-Pilot study investigating the impact of CardiolRx&#x2122; administered to patients with symptomatic recurrent pericarditis. The data showed that the marked improvements in both pericarditis pain and inflammation, previously reported at the 8-week primary endpoint, were maintained throughout the extension period of the 26-week study. The data were included in an oral presentation as part of the Laennec Clinician-Educator Award &amp; Lecture at the American Heart Association Scientific Sessions 2024. Dr. S. Allen Luis, Co-Director of the Pericardial Diseases Clinic and Associate Professor of Medicine in the Department of Cardiovascular Medicine at the Mayo Clinic, presented on behalf of the MAvERIC-Pilot investigators. These findings support the initiation of a Phase III trial (MAVERIC-3), designed to assess CardiolRx&#x2122; for the treatment of pericarditis patients to prevent recurrence. The MAVERIC-3 trial is expected to run in parallel with the recently announced MAVERIC-2 Phase II/III trial designed to evaluate the impact of CardiolRx&#x2122; in recurrent pericarditis patients following cessation of interleukin-1 blocker therapy.

Biotech

General

CRDL

Cardiol Therapeutics' Presents Phase II MAvERIC-Pilot Clinical Results In Recurrent Pericarditis Presented At The AHA Scientific Sessions 2024; Marked And Rapid Reductions In Both Pericarditis Pain And Inflammation Maintained Throughout The 26-Week Study

HC Wainwright &amp; Co. analyst Raghuram Selvaraju maintains Inovio Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>) with a Neutral and lowers the price target from $12 to $5.

HC Wainwright & Co. Maintains Neutral on Inovio Pharmaceuticals, Lowers Price Target to $5

WestPark Capital analyst Casey Ryan reiterates Glimpse Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRAR#NASDAQ">VRAR</a>) with a Buy and maintains $2.65 price target.

VRAR

WestPark Capital Reiterates Buy on Glimpse Group, Maintains $2.65 Price Target

Offerings

On Friday November 15, 2024, Safe And Green Development Announced Prospectus For Resale Of 1.29M Common Shares By Selling Stockholders, Including Arena Special Opportunities Partners And Arena Global

<a href="https://www.cdc.gov/bird-flu/spotlights/h5n1-response-11152024.html" title="https://www.cdc.gov/bird-flu/spotlights/h5n1-response-11152024.html">https://www.cdc.gov/bird-flu/spotlights/h5n1-response-11152024.html</a>

NVAX

U.S. CDC Says Since April Confirmed Avian Influenza A(H5) Virus Infections In 52 People In US; Aware Of Human Case Of H5N1 Bird Flu Reported In Canada & Is In Communication With Public Health Agency Of Canada

On Friday November 15, 2024, Safe And Green Development Announced Amended ELOC Purchase Agreement With Arena Business Solutions Global SPC II; Issues Pre-Funded Warrant For 83,333 Shares, Ensures $250K Value For Second Tranche Commitment Fee Shares

Alphabet, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) Google announced its AI assistant Gemini is now available for download on Apple, Inc's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) iPhone <a href="https://www.benzinga.com/tech/24/11/41891904/googles-standalone-gemini-app-for-iphone-spotted-with-live-activity-what-it-could-mean-for-your-ai-experience">as an app. </a>
The Details: Google said <a href="https://blog.google/products/gemini/gemini-iphone-app/">the dedicated</a> Gemini app is now available in the iOS App Store and highlighted the ability to have a "free-flowing conversation" with Gemini by clicking the Gemini Live button within the iPhone app.&nbsp;
Google touts the Gemini Live feature as ideal for brainstorming and creative thinking processes because users can interrupt Gemini to ask a question or to change the topic.&nbsp;
Read More:<a href="https://www.benzinga.com/markets/24/11/42006626/trump-media-insiders-sell-more-than-16-million-in-djt-stock"> Trump Media Insiders Sell More Than $16 Million In DJT Stock</a>
Salesforce.com, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>) CEO Marc Benioff <a href="https://www.benzinga.com/tech/24/11/42030837/salesforce-ceo-marc-benioff-lauds-googles-truly-groundbreaking-gemini-ai-after-taking-jabs-at-microsofts-copilot">praised</a> Gemini Live's zero latency and labeled it the "future of consumer AI" in a social media post this weekend.&nbsp;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Just downloaded Gemini Live, and I'm absolutely blown away. Speaking directly to AI with zero latency—this voice interaction is the future of consumer AI. Incredible work, <a href="https://twitter.com/sundarpichai?ref_src=twsrc%5Etfw">@sundarpichai</a>. Truly groundbreaking. Try it immediately: <a href="https://t.co/PysnzJsh7f">https://t.co/PysnzJsh7f</a>"
&mdash; Marc Benioff (@Benioff) <a href="https://twitter.com/Benioff/status/1858259054277415292?ref_src=twsrc%5Etfw">November 17, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Bloomberg columnist Mark Gurman expects a Gemini <a href="https://www.benzinga.com/media/24/11/42030331/heres-when-google-gemini-could-be-integrated-with-apple-intelligence">integration to come</a> to Apple Intelligence sometime in 2025. However, it remains unclear whether this will occur in the spring iOS 18.4 release, or later in the year during the iOS 19 release cycle.&nbsp;
For now, iPhone users can use the Gemini app to chat using Gemini Live, create AI-generated images from text and connect to other Google apps like YouTube, Google Maps, Gmail and Calendar using Extensions. 
Google also highlighted the Gemini app as a tool for students who can upload images or text and have Gemini create a study guide or quiz from the material. Gemini can also provide custom, step-by-step guidance that adapts to the user&#8217;s learning style. 
The app is currently available in more than 10 languages, with additional languages coming soon.
GOOG Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Alphabet shares are up 0.96% at $175.56 at the time of publication Monday. 
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/24/11/41949068/bitcoin-could-reach-1-million-by-2037-economist-says-buy-of-a-lifetime-opportunity">Bitcoin Could Reach $1 Million By 2037, Economist Says: &#8216;Buy Of A Lifetime&#8217; Opportunity</a></li>
</ul>
Image: Shutterstock

Large Cap

Tech

AAPL

GOOG

GOOGL

Google's Gemini App Brings 'Free-Flowing' AI To Apple iPhone

Hepion ends Phase 2 study for NASH drug due to cash restraints

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
It&rsquo;s time to start off the trading week with a look at the biggest pre-market stock movers for Monday morning!



Moving stocks this morning are earnings, investments, a delisting and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Moolec Science (NASDAQ:<a href="https://investorplace.com/stock-quotes/mlec-stock-quote/">MLEC</a>) stock is rocketing more than 67% on approval for its <a href="https://www.nasdaq.com/press-release/moolec-becomes-first-molecular-farming-company-to-achieve-usda-approval-for-plant">plant-groan animal proteins</a>.</li>



<li>OLB Group (NASDAQ:<a href="https://investorplace.com/stock-quotes/olb-stock-quote/">OLB</a>) shares are soaring over 46% with heavy pre-market trading.</li>



<li>Complete Solaria (NASDAQ:<a href="https://investorplace.com/stock-quotes/cslr-stock-quote/">CSLR</a>) stock is surging more than 42% <a href="https://www.nasdaq.com/press-release/retail-stock-sector-and-chairman-t.j.-rodgers-invest-in-complete-solaria-2024-04-21">on investment news</a>.</li>



<li>SuperCom (NASDAQ:<a href="https://investorplace.com/stock-quotes/spcb-stock-quote/">SPCB</a>) shares are gaining over 33% ahead of its <a href="https://www.nasdaq.com/press-release/supercom-to-report-fourth-quarter-and-full-year-2023-financial-results-on-april-22">Q4 2023 earnings report</a> this morning.</li>



<li>Dermata Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/drma-stock-quote/">DRMA</a>) stock is rising more than 18% on Monday morning.</li>



<li>Galera Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/grtx-stock-quote/">GRTX</a>) shares are increasing over 17% without any clear news this morning.</li>



<li>Palisade Bio (NASDAQ:<a href="https://investorplace.com/stock-quotes/pali-stock-quote/">PALI</a>) stock is climbing more than 16% despite a lack of news today.</li>



<li>Global Gas (NASDAQ:<a href="https://investorplace.com/stock-quotes/hgas-stock-quote/">HGAS</a>) shares are heading over 14% higher on Monday.</li>



<li>Volato (NYSEMKT:<a href="https://investorplace.com/stock-quotes/soar-stock-quote/">SOAR</a>) stock is jumping more than 13% on Monday morning.</li>



<li>Portage Biotech (NASDAQ:<a href="https://investorplace.com/stock-quotes/prtg-stock-quote/">PRTG</a>) shares are up over 13% today.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Vaxxinity (NASDAQ:<a href="https://investorplace.com/stock-quotes/vaxx-stock-quote/">VAXX</a>) stock is crashing more than 55% on the company&rsquo;s <a href="https://finance.yahoo.com/news/vaxxinity-announces-intention-voluntarily-delist-202700884.html">plans to delist its shares</a>.</li>



<li>EzFill (NASDAQ:<a href="https://investorplace.com/stock-quotes/ezfl-stock-quote/">EZFL</a>) shares are plummeting close to 37% this morning.</li>



<li>Hepion Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/hepa-stock-quote/">HEPA</a>) stock is diving over 29% on plans to <a href="https://www.nasdaq.com/press-release/hepion-pharmaceuticals-initiates-wind-down-activities-in-phase-2b-ascend-nash-trial">wind down a clinical trial</a>.</li>



<li>iLearningEngines (NASDAQ:<a href="https://investorplace.com/stock-quotes/aile-stock-quote/">AILE</a>) shares are tumbling more than 21% after <a href="https://finance.yahoo.com/news/ilearningengines-inc-becomes-publicly-traded-200500132.html">going public last week</a>.</li>



<li>Redwoods Acquisition (NASDAQ:<a href="https://investorplace.com/stock-quotes/rwod-stock-quote/">RWOD</a>) stock is taking an over 15% beating <a href="https://investorplace.com/2024/04/why-is-redwoods-acquisition-rwod-stock-up-72-today/">after a recent rally</a>.</li>



<li>Biophytis (NASDAQ:<a href="https://investorplace.com/stock-quotes/bpts-stock-quote/">BPTS</a>) shares are sliding more than 15% ahead of <a href="https://www.nasdaq.com/press-release/biophytis-announces-ratio-change-under-its-american-depositary-receipt-adr-program-0">a ratio change tomorrow</a>.</li>



<li>Adlai Nortye (NASDAQ:<a href="https://investorplace.com/stock-quotes/anl-stock-quote/">ANL</a>) stock is dropping nearly 15% today.</li>



<li>BioSig Technologies (NASDAQ:<a href="https://investorplace.com/stock-quotes/bsgm-stock-quote/">BSGM</a>) shares are falling over 13% this morning.</li>



<li>Sunshine Biopharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/sbfm-stock-quote/">SBFM</a>) stock is decreasing more than 12% today.</li>



<li>Indonesia Energy (NYSEMKT:<a href="https://investorplace.com/stock-quotes/indo-stock-quote/">INDO</a>) shares close out our pre-market stock movers down over 10%.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/04/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-monday-april-22nd/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

SBFM, BPTH and INDO among pre-market losers

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Hepion Pharmaceuticals&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/hepa-stock-quote/">HEPA</a>) stock is diving on Monday after the biopharmaceutical company announced plans to <a href="https://www.nasdaq.com/press-release/hepion-pharmaceuticals-initiates-wind-down-activities-in-phase-2b-ascend-nash-trial">wind down a clinical trial</a>.



A press release from the company notes that it is winding down it Phase 2b ASCEND-NASH study. The failure of the study comes as it couldn&rsquo;t reach the planned 336 patients. Instead, it only got to 151 patients.



On top of this, Hepion Pharmaceuticals is struggling with resources as the company is exploring strategic alternatives. This didn&rsquo;t leave it with enough room to keep the trial going while waiting for more patients to enroll.



Hepion Pharmaceuticals executive chairman John Brancaccio said the following about the news.




&ldquo;We are disappointed to announce the wind-down of our Phase 2 NASH trial, which we attribute entirely to resource constraints. Given the number of enrolled NASH patients to date and the low probability of generating relevant efficacy data to support a registrational trial with our current cash resources, we have opted to wind down the program and assure that patients are transitioned out of the trial in a safe and compliant manner.&rdquo;




<h2>HEPA Stock Movement Today</h2>



With this news comes a 40.5% drop for HEPA stock on Monday morning. Investors will note that the shares were already down 36.2% year-to-date when markets closed on Friday.



This also comes with around 39,000 shares traded. The company&rsquo;s daily average trading volume is still above that at 75,000 shares.



Investors will find even more of the most recent stock market stories ready to go below!



We are offering insight into the top stock market news for Monday! That includes everything happening with shares of Vaxxinity&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/vaxx-stock-quote/">VAXX</a>) stock, OLB Group&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/olb-stock-quote/">OLB</a>) stock and Moolec Science&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/mlec-stock-quote/">MLEC</a>) stock today. You can find out more on these matters at the following links!



<h2>More Stock Market News for Monday</h2>



<ul><li><a href="https://investorplace.com/2024/04/why-is-vaxxinity-vaxx-stock-down-58-today/">Why Is Vaxxinity (VAXX) Stock Down 58% Today?</a></li>



<li><a href="https://investorplace.com/2024/04/why-is-olb-group-olb-stock-up-27-today/">Why Is OLB Group (OLB) Stock Up 27% Today?</a></li>



<li><a href="https://investorplace.com/2024/04/why-is-moolec-science-mlec-stock-up-121-today/">Why Is Moolec Science (MLEC) Stock Up 121% Today?</a></li>
</ul>On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>



On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/04/why-is-hepion-pharmaceuticals-hepa-stock-down-41-today/">Why Is Hepion Pharmaceuticals (HEPA) Stock Down 41% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is Hepion Pharmaceuticals (HEPA) Stock Down 41% Today?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Nike (NYSE:<a href="https://investorplace.com/stock-quotes/nke-stock-quote/">NKE</a>) layoffs are in the news Monday after the athletic apparel company announced plans to <a href="https://www.kgw.com/article/money/business/nike-740-layoffs-world-headquarters-beaverton/283-3d676a3c-957d-4110-92bd-d5f7a9c793e9">cut jobs at its global headquarters</a>.



These Nike layoffs will result in 740 employees at the company&rsquo;s Beaverton, Oregon, headquarters losing their jobs. This comes after the company announced plans to reduce its workforce by 2% in February.



Nike is planning to handle these layoffs in two rounds. The first round will start immediately, and the second round will <a href="https://www.usatoday.com/story/money/business/2024/04/20/nike-layoffs-2024/73396096007/">start by June 28</a>. It&rsquo;s worth noting that Nike currently has about 11,000 employees at its headquarters and 83,000 total.



All of this is part of a restructuring effort that has 1,600 jobs being cut at Nike. The company estimates that these changes will save it $2 billion per year and that it will suffer a $400 million to $450 million charge connected to them.



<h2>Nike Layoffs Statement</h2>



Here&rsquo;s what the company had to say about the layoffs to KGW8:




&ldquo;Nike&rsquo;s always at our best when we&rsquo;re on the offense. The actions that we&rsquo;re taking put us in the position to right-size our organization to get after our biggest growth opportunities as interest in sport, health and wellness have never been stronger.&rdquo;




NKE stock is down slightly on Monday morning after announcing this newest round of layoffs.



Investors who are seeking out even more of the most recent stock market stories are in luck!



We have all of the hottest stock market news for Monday! Among that is what has shares of Tesla&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/tsla-stock-quote/">TSLA</a>), Hepion Pharmaceuticals&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/hepa-stock-quote/">HEPA</a>) and Vaxxinity (NASDAQ:<a href="https://investorplace.com/stock-quotes/vaxx-stock-quote/">VAXX</a>) stock in the news today. You can read up on all of this news at the links below!



<h2>More Monday Stock Market News</h2>



<ul><li><a href="https://investorplace.com/2024/04/tsla-stock-alert-tesla-plunges-on-another-round-of-ev-price-cuts/">TSLA Stock Alert: Tesla Plunges on Another Round of EV Price Cuts</a></li>



<li><a href="https://investorplace.com/2024/04/why-is-hepion-pharmaceuticals-hepa-stock-down-41-today/">Why Is Hepion Pharmaceuticals (HEPA) Stock Down 41% Today?</a></li>



<li><a href="https://investorplace.com/2024/04/why-is-vaxxinity-vaxx-stock-down-58-today/">Why Is Vaxxinity (VAXX) Stock Down 58% Today?</a></li>
</ul>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/04/nike-layoffs-2024-what-to-know-about-the-latest-nike-job-cuts/">Nike Layoffs 2024: What to Know About the Latest Nike Job Cuts</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Nike Layoffs 2024: What to Know About the Latest Nike Job Cuts

MRIN, WISA and SMFL among mid-day movers

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Hepion Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/hepa-stock-quote/">HEPA</a>) just reported results for the first quarter of 2024.<ul><li>Hepion Pharmaceuticals reported earnings per share of -56 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/hepa-stock-earnings-hepion-pharmaceuticals-for-q1-of-2024/">HEPA Stock Earnings: Hepion Pharmaceuticals Reported Results for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

HEPA Stock Earnings: Hepion Pharmaceuticals Reported Results for Q1 2024

An update from Hepion Pharmaceuticals (HEPA) is now available. Hepion Pharmaceuticals has entered into a merger agreement with Pharma Two B Ltd. an...

Hepion Pharmaceuticals' Strategic Merger and Corporate Restructuring

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Hepion Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/hepa-stock-quote/">HEPA</a>) just reported results for the second quarter of 2024.<ul><li>Hepion Pharmaceuticals reported earnings per share of -68 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/hepa-stock-earnings-hepion-pharmaceuticals-for-q2-of-2024/">HEPA Stock Earnings: Hepion Pharmaceuticals Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

HEPA Stock Earnings: Hepion Pharmaceuticals Reported Results for Q2 2024

Pharma Two B and Hepion Pharmaceuticals (HEPA) announced that the U.S. Securities and Exchange Commission has declared effective the registration s...

Hepion, Pharma Two B announce effectiveness of registration statement for merger

AGBA

AILE

AKRO

ARWR

ASCLF

BPTH

BPTS

BSGM

CAPT

CHRO

CSLR

DRMA

EDBL

ETNB

EZFL

GALT

GILD

GLMD

GRTX

HEPA

HGAS

HUBC

INDO

INVO

IONS

MDGL

MDIA

MLEC

MNDR

MRIN

MTTR

NKGN

NVFY

PAAS

PALI

PROK

PRTG

RWOD

SBFM

SGMT

SMFL

SOAR

SPCB

TELO

TERN

TRSG

TSLA

VAXX

VKTX

VZLA

WISA

YYGH

ZCMD

Press Releases

Hepion Pharmaceuticals to Present at the 7th Obesity & NASH Drug Development Summit

Hepion Pharmaceuticals Announces Restructuring Plan to Enhance Shareholder Value and Management Changes

Hepion Pharmaceuticals to Present at NASH-TAG 2024

Hepion Pharmaceuticals Announces Exercise of Warrants for Approximately $2.0 Million Aggregate Gross Proceeds

Hepion Pharmaceuticals Strengthens Board of Directors with Appointment of Michael Purcell

Hepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b 'ASCEND-NASH' Trial

Pharma Two B Announces Plans to Go Public via Merger with Hepion Pharmaceuticals, Inc. and Concurrent $11.5 Million Private Placement

Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Filing of Registration Statement on Form F-4 Related to Proposed Merger

Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Effectiveness of Registration Statement Related to Proposed Merger

Comments

Hepion Pharmaceuticals

Hepion Pharmaceuticals (HEPA) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL